The Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (5), Page 2448-2454

Treatment of Adult Patients with Short-Bowel Syndrome

Muayyad Abdullah Abualjadayel[1], Mansour Ali Shaiban[2], Norah Abdulaziz Alhatim[3], Mohammed Riyadh A Alabbad[4], Anas Salah Almiro[5], Fatmah Ibrahim Alrawaji[3], Alaa Eid Aljohani[6], Ali Abdulazeem Habeeb[7], Mohammed Sunaytan Al Otaibi[8], Nedal Mohammed Alhababi[4]

1- Umm Alqura University, 2- Jazan University, 3- Al Maarefa Colleges, 4- Imam Abdulrahman Bin Faisal University, 5 -University of Science and Technology, 6- Ohud Hospital – Almedina Almonwra, 7- Imam Abdulrahman Bin Faisal University, 8- Security Forces Hospital

Corresponding author: Muayyad Abdullah Abualjadayel - King21monstar@hotmail.com - 0546993163

ABSTRACT

Background: extensive resection of the intestinal tract regularly results in insufficient digestion and absorption of nutrients, a condition identified as short bowel syndrome. This condition requests a devoted multidisciplinary collaboration to overcome the morbidity and mortality in these patients. With progresses in serious care management, an increased number of patients survive the prompt morbidity of massive intestinal resection present with short bowel syndrome. Some treatments, including parenteral nutrition and surgical methods to reconstruct bowel have been utilized in these patients. Dietary methods, pharmacotherapy and convenient surgical interventions have all added to the enhanced result in these patients. Nevertheless, increasing experience and promising outcomes of intestinal transplantation had added a new aspect to the administration of short bowel syndrome.

Keywords: intestinal, extensive, malabsorption, short bowel syndrome, total parenteral nutrition.

INTRODUCTION

Short-bowel syndrome is a disorder clinically defined by steatorrhea, malabsorption, diarrhea, malnutrition, fluid and electrolyte disturbances. The final mutual etiologic factor in all causes of short-bowel syndrome is the functional or anatomic loss of extensive segments of small intestine so that absorptive capacity is severely compromised. Even though resection of only the colon normally does not outcome in short-bowel syndrome, the condition's incidence may be a serious factor in the treatment of patients who lose substantial amounts of the small intestine [1, 2].

Great small intestinal resection compromises digestive and absorptive procedures. Satisfactory digestion and absorption can't happen and accurate nutritional status can't be preserved without supportive care. Currently, the most mutual causes of short-bowel syndrome in adults contain Crohn disease [3], radiation enteritis, trauma, mesenteric vascular accidents and recurrent intestinal obstruction. In the pediatric populace, intestinal atresias, necrotizing enterocolitis and intestinal volvulus are the most well-known etiologic factors. Different conditions related with short-bowel syndrome incorporate congenital short small bowel, gastroschisis and meconium peritonitis.

Numerous operative or intrusive procedures and treatments have been considered and applied to the treatment of short-bowel syndrome. This incorporates the creation of central venous access for delivery of total parenteral nutrition (TPN), non-transplantation abdominal operations and intestinal transplantation. TPN was produced effectively by **Dudrick *et al.*** [4]. Their paper included research facility in a canine model and clinical outcomes in 30 grown-up patients with an assortment of gastrointestinal (GI) diseases extending from achalasia, horrendous pancreatitis to territorial enteritis. The creature display unmistakably exhibited viability.

Beagle puppies bolstered altogether intravenously outperformed their littermate controls in weight pick up and were equivalent as far as action level, skeletal development and other formative points of interest. In the clinical arm of the examination [4], 30 subjects accepting TPN could accomplish positive nitrogen adjust, look after weight, mend wounds and close fistulae. **Wilmore and Dudrick** [5] detailed positive nitrogen adjust, development and advancement in a baby conceived with diffusely atretic little inside who was bolstered totally parenterally.

After these early achievements, the new technique was brought into the clinical standard, and signs for its utilization had extended

Received:26 /8 /2017
Accepted: 5 /9 /2017
DOI : 10.12816/0041692

immensely. Patients with short-bowel syndrome were presently routinely treated with TPN, particularly prompt in their course. New remedial procedures that might enable patients to cease or curtail the utilization of TPN were discussed in consequent sections. The principal effective consolidated transplantation of small digestive system and liver in a human was performed in 1990. Since that time, the system of confined little intestinal transplantation has been created and connected. Better unite survival rates were accomplished when patients get their transplant before entanglements optional to short-bowel syndrome happen, particularly that of cirrhosis [6].

MATERIALS AND METHODS

- **Data sources and search terms**

We conducted this review using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials from January 1, 1965, through March 28, 2017.

- **Data Extraction**

Two reviewers independently reviewed studies, abstracted data and resolved disagreements by consensus. Studies were evaluated for quality. A review protocol was followed throughout:

PATHOPHYSIOLOGY

Physiologic disorders in short-bowel syndrome are the consequence of the loss of large quantities of intestinal absorptive surface area. The sequelae of this loss contain malabsorption of water, electrolytes, macronutrients (i.e., proteins, fats, carbohydrates,), and micronutrients (i.e., vitamins, trace elements, minerals).

The GI tract is a vital locus for water and electrolyte absorption and transport. Along with treatment exogenously obtained sources of these nutrients, for example, daily water consumption and the electrolytes found in liquid and solid foods, the GI tract should contend with its own substantial daily secretions. The nature and efficiency of this assignment is explained by **Sellin** [7], who transcripts that the GI tract processes 8000-9000 mL of fluid every day, with the huge majority of this resulting from endogenous secretions. Fluid reabsorption by the healthy GI tract is efficient (98%) and only 100-200 mL is lost in faecal matter every day. The excessive majority (80%) of this reabsorption may be falls in the small intestine. Macronutrients and micronutrients are assimilated along the length of the small digestive tract. The jejunum has taller villi, more profound sepulchers and more noteworthy chemical action than the ileum [8].

Therefore, under ordinary conditions, around 90% of assimilation and retention of critical macronutrients and micronutrients is expert in the proximal 100-150 cm of the jejunum [9]. This incorporates ingestion of proteins, sugars, fats, vitamins B, C, and folic corrosive and the fat-solvent vitamins A, D, E and K. Protection of the colon have positive and negative characteristics. **Philips and Giller** [10] showed that colonic water assimilation could be expanded to as much as five times its ordinary limit following little inside resection.

Likewise, by temperance of its occupant microscopic organisms, the colon has the natural ability to process undigested starches into short-chain unsaturated fats, for example, butyrate, propionate and acetic acid derivation. This is a favoured fuel hotspot for the colon. Strangely, **Pomare *et al***. [11] exhibited that the colon can absorb up to 500 kcal day by day of these metabolites, which at that point can be transported by means of the entry vein to be utilized as a substantial fuel source.

In contrast, preservation of the colon increases the frequency of urinary calcium oxalate stone formation. Oxalate is generally bounded by calcium in the small bowel and accordingly is difficult when it influences the colon. After considerable enterectomy, much of this calcium is bounded by free intraluminal fats. Free oxalate is brought to the colon, where it is absorbed. This may ultimately lead to saturation of the urine with calcium oxalate crystals and outcome in stone formation. Retention of the colon in the absence of a competent ileocecal valve may lead to small intestinal bacterial overgrowth.

The physiologic changes and adaptation of patients with short-bowel syndrome can be observed in **table 1** [12].

Table 1: the three phases of the physiologic changes and adaptation of patients with short-bowel syndrome

Acute phase	Adaptation phase	Maintenance phase
Starts immediately after bowel resection and lasts 1-3 months	Begins within 48 hours of resection and lasts up to 1-2 years	The absorptive capacity of the intestine is at its maximum
Ostomy output of greater than 5 L/day	Approximately 90% of the bowel adaptation takes place during this phase	Nutritional and metabolic homeostasis can be achieved by oral feeding, or patients are committed to receiving supplemental or complete nutritional support for life
Life-threatening dehydration and electrolyte imbalances	Enterocyte hyperplasia, villous hyperplasia, and increased crypt depth occur, resulting in increased surface area; intestinal dilatation and lengthening also occur	
Extremely poor absorption of all nutrients	Luminal nutrition is essential for adaptation and should be initiated as early as possible; parenteral nutrition is also essential throughout this period	
Development of hypergastrinemia and hyperbilirubinemia		

Treatment of patients with Short-Bowel Syndrome

Most survivors of massive bowel resections who improve short-bowel syndrome are primarily nourished by means of total parenteral nutrition (TPN). In these patients, TPN avoids the improvement of malnutrition and has been appeared to help patient outcomes. TPN might be managed simultaneously with enteral nutrition right on time in the clinical course of short-bowel syndrome as the critical goal in many of these patients is to improve intestinal adaptation and render patients free of TPN as defined by **Wilmore *et al.*** [12] in animal models . In numerous patients, intestinal adjustment, alone or in mix with altered and supplemented diets (e.g., development hormone, glutamine, high sugar, low fat) as depicted by **Byrne *et al.*** [13] in the long run permits freedom from TPN. A few patients are to a great degree troublesome or difficult to wean from parenteral sustenance. Basic qualities of these patients incorporate small bowel segments (<60 cm), loss of the colon, loss of the ileocecal valve, or small-bowel strictures with stasis and bacterial excess. TPN isn't a panacea. Access destinations wind up noticeably contaminated or the cannulated vein thromboses, requiring substitution. Notwithstanding these mechanical and irresistible inconveniences, numerous genuine metabolic complexities are related with long haul utilization of TPN. The most clinically essential of these are hepatic and biliary confusions. In actual fact, according to **Vanderhoof**[14]propelled liver malady as it is the most well-known reason for death of patients with short-bowel syndrome. Early in the course of treatment with TPN, general elevations in hepatic transaminases may be found. Regularly, these biochemical irregularities are self-limited and need no precise alteration or restriction of treatment. The most regular indication of hepatobiliary ailment in patients with short-bowel syndrome who are on TPN is cholestasis. Biliary slime or gallstones are found in roughly half of patients getting TPN with no oral admission for 3 months. Progressive hepatic parenchymal harm is the most dreaded hepatobiliary difficulty of delayed TPN. Non-alcoholic steatohepatitis has highlights of greasy change however it is related with fiery cell penetration and fibrosis. Dynamic cholestasis and liver damage can be prompted by large entry fibrosis or cirrhosis, forecasting movement to liver disappointment and a poor result [15]. **Moreno *et al.*** [16] announced intricacy rates and survival information for their accomplice of 74 patients kept up on long haul home parenteral

nourishment for short-inside disorder. There were 94 huge inconveniences in the gathering, the greater part of them were irresistible. Toward the finish of the year, 74.3% of the patients stayed on TPN. The most widely recognized reason for end of help in the other 23.6% was passing (52.9%). Others were either changed to enteral dietary help (11.8%) or could be freed from particular wholesome help to come back to an oral eating routine (23.5%).

Surgical Treatment

Operative treatments for short-bowel syndrome are divided into two broad categories:

- Intestinal or combined liver-intestinal transplantation
- Nontransplant operations.

Nontransplant components of the surgical armamentarium for the management of short-bowel syndrome comprise intestinal lengthening (Bianchi) procedures, strictureplasty, intestinal tapering for dilated dysfunctional bowel segments and creation of intestinal valves or reversed bowel segments for patients with rapid intestinal transit periods.**Thompson and Langnas** [17] reported additional results from nontransplant operations for treatment of short-bowel syndrome. 90 patients were assessed for promising surgical therapy. Of 43 procedures, 37 (86%) produced clinical improvement. The best outcomes were attained with operations designed to increase intestinal surface area, for example, restoration of gastrointestinal (GI) tract continuity and intestinal lengthening (86%) and those intentional to correct functional issues, for example, strictureplasty, closure of fistulae and removal of diseased bowel segments (85%). Clinical enhancement rates of just 50% were observed with operations targeted at slowing intestinal transit period, such as creation of valves or reversed segments.

Conversely, **Panis** [18] detailed great outcomes with segmental little gut inversion. However, his arrangement was little (N = 8). The patients had short-bowel syndrome leftovers (middle, 40 cm). The middle length of the switched portion was 12 cm. One patient kicked the bucket of aspiratory embolism in postoperative month 7. Of the staying seven patients, three were totally freed from parenteral sustenance, one required just IV liquid and electrolyte treatment and three got just three to five night time cycles of parenteral nourishment every week. **Javid *et al.*** [19] distributed their outcomes with serial transverse enteroplasty (STEP) for the treatment of short-bowel syndrome in new-born children. An aggregate of five kids experienced this intestinal lengthening method. No huge perioperative confusions were accounted. The level of protein-energy nutrition that the patients could take enterally expanded fundamentally in this gathering following STEP ($P < 0.05$). One child was totally freed from parenteral sustenance and another child's serious cholestasis was turned around. **Oliveira *et al.*** [20] analyzed 5-year results after STEP in 12 youngsters (middle age, 5.5 months) with short-bowel syndrome. Of these 12 patients, two experienced liver-intestinal transplants and two kicked the bucket of liver disappointment, while the other eight all displayed stable intestinal absorptive limit at development. Among these eight patients, seven were weaned off parenteral sustenance by age four. Rehash step or bowel tapering was a bit much in any of the patients. Organ transplantation was an advanced adding to surgical treatment of this syndrome. From the beginning, intestinal transplantation faced numerous difficulties, first and primary due to the huge amount of lymphoid and immunologic tissue allied with the GI tract. Effective immunosuppressant medications had to be developed. Procedures and postoperative care had to be developed and the signs for transplantation had to be illuminated. All over the world, valued 25-30 centres are actively involved in intestinal or liver-intestinal transplantation for short-bowel syndrome. **Abu-Elmagd *et al.*** [21] refreshed the University of Pittsburgh involvement with liver-intestinal and separated intestinal transplantation. Their outcomes in 59 grown-ups and 39 youngsters were exhibited. These patients got either liver-intestinal (n = 50), disengaged intestinal (n = 37), or multivisceral (n = 17) unites. Twenty were increased with contributor bone marrow. Tacrolimus was the essential immunosuppressant utilized as a part of all cases. With a mean follow-up length of 32 months, 48% of patients were bursting at the seams with joins that permitted finish (91%) or halfway (9%) freedom from particular dietary help. Also, 12 patients had passed the 5-year breakthrough. The actuarial patient survival rates at 1 and 5 years were 72% and 48%, individually. Bone marrow transplantation did not seem to expand join survival. **Sudan *et al.***[22]distributed their clinical consequences of intestinal extending methodology. A result examination of a longitudinal intestinal stretching (Bianchi procedure) and a serial transverse enteroplasty (STEP procedure) was finished. Fifty paediatric patients and 14 grown-up patients were

incorporated into the examination. All patients had expanded little inside circles more prominent than 3.9 cm in estimate and furthermore had poor enteral movement. The patients experienced 43 Bianchi systems and 34 STEP methods. The normal intestinal length expanded from 44 cm to 68 cm for the Bianchi technique and from 45 cm to 65 cm for the STEP strategy. At 1 year after the protracting methodology, 69% of the patients were off aggregate parenteral nourishment (TPN). The authors of this investigation reasoned that surgical extending systems result in a change in enteral nourishment.

Practical details

Patient selection is vital to operative achievement. Tailor non-transplant operative methods to the patient's outstanding length of intestine, the attendance or absence of strictures or areas of stasis, bowel dilatation and the intestinal transit time as defined above. Several radiographic methods, comprising contrast small-bowel follow-through and computed tomography (CT) are supportive in the decision. Transplant surgery is normally saved for patients who are reliant on parenteral sustenance, who have come up short on venous access, who have had a few scenes of focal line– related sepsis, or who have started to show dynamic parenteral nutrition–related liver brokenness. Recognize these patients early and perform transplant before hepatic cirrhosis creates. This may hinder the need to play out a consolidated liver-intestinal transplantation, and results are better in patients who have not yet created cirrhosis, as indicated by **Vanderhoff and Langnas** [25].

In the study carried out by **Abu-Elmagd *et al***. grafts were acquired from blood group (ABO) antigen-matched cadaveric contributors. Although human leukocyte antigen (HLA) coordinating was performed, it was poor and 13 patients in their arrangement had lymphocytotoxic positive cross-matches. Even though a full discussion of the operative technique is beyond the scope of this article, a brief outline of the procedures of combined liver small bowel transplantation and isolated small bowel transplantation is worthwhile. Some details that bear discussion here were published by **Abu-Elmagd *et al.*** [23]. The University of Wisconsin solution was used for graft preservation. These authors have conserved the donor enteric and celiac ganglia as a measure to decrease postoperative graft dysmotility. Nontransplant procedures need meticulous technique too. The bowel should be controlled gently and the blood supply guarded carefully.

Abdominal visceral organ acquisition may start with an endeavour at GI tract cleansing by intragastric organization of a nonabsorbable anti-microbial suspended in a cathartic arrangement. Proximal and distal stomach aortic control is accomplished at the aortic break and caudal to the sub-par mesenteric conduit. The proximal aorta is cinched and the distal aorta is cannulated. Cold preservation solution is utilized to perfuse the abdominal viscera to be extracted and transplanted. Seepage is given by the formation of a venotomy in the suprahepatic sub-par vena cava. The bowel is stapled proximally and distally. Other instinctive vascular associations are separated and the join example was expelled. On the off chance that the patient gets a transplant comprising the liver and digestive system, GI tract progression is re-established by proximal and distal anastomosis. Few creators have instructed creation with respect to proximal and distal stomas by means of appendages of digestive system on the grounds that delayed intestinal decompression might be vital in the early postoperative period. Arterial blood supply is restored by anastomosis of a Carrel fix of the celiac hub and better mesenteric course than the aorta, or if benefactor aorta is incorporated, an aorto-aortic anastomosis is conceivable. Venous seepage of the digestive system is in place to the liver in a consolidated hepatic-intestinal transplant. Hepatic venous drainage can be accomplished by harvesting donor retrohepatic inferior vena cava with protection of the donor hepatic veins distally. This is anastomosed to the recipient inferior vena cava circumferentially. Consecutively, the donor inferior vena cava can be anastomosed to the recipient vena cava via an anterior venotomy. This anastomosis piggybacks the hepatic venous outflow onto the anterior surface of the recipient vena cava. This requires ligation of the caudal aspect of the donor inferior vena cava. Venous outflow for the recipient's retained organs, for example, the stomach, pancreas, and duodenum, could be established by anastomosis of the recipient portal vein to the donor vena cava or the donor portal vein. When isolated intestinal grafts are utilized, a Carrel patch of the donor superior mesenteric artery is anastomosed to the recipient aorta. A long segment of donor superior mesenteric and portal vein is conserved for anastomosis to the recipient portal vein. GI tract continuousness is re-established as defined above.

Medical Treatment

Parenteral nutrition is a significant treatment in the care of the patient with short bowel

syndrome. Parenteral nutrition offers adequate protein, calories, other macronutrients, and micronutrients until the bowel had time to adapt. The time necessary for optimal bowel adaptation is a source of argument. **Booth** [24] stated that bowel adaptation might not be complete until 1 year or more after resection. **Carbonnel *et al.*** [25] reported that little bowel compensation occurs after 3 months data from animal studies conducted by **Wilmore *et al.*** [4] suggested that supplementing enteral intake with parenteral nutrition early in the postoperative course results in better overall bowel adaptation. This is most likely because it facilitates provision of adequate calorie and nitrogen sources. According to **Nightingale *et al.*** [26] when enteral nutrient absorption falls to below one third of premorbid capacity, some amounts of parenteral nutrition is wanted. Parenteral nutrition may be started with standard formulations and managed over the course of 24 hours per day on an inpatient basis. Make efforts to infuse daily requests in shorter time periods before the patient is discharged. This is named cycling and it permits liberation from the solution pump for at least some time every day. Furthermore, laboratory studies, comprising serum chemistries and mineral and trace element levels are monitored frequently and provision of these nutrients adjusted consequently in the parenteral nutrition formula. Progressively, most patients are capable to resume and increase oral food consumption. This begins by providing small common feedings and slowly advancing the diet as tolerated. A subset of patients who have lost critical measures of ileum and colon may have enormous liquid misfortunes. Stomal yields may surpass 2.5 L/day. A considerable lot of these patients are probably going to be subject to delayed intravenous (IV) liquid treatment. Some may do well with oral wellsprings of water, glucose and sodium. Wilmore's gathering revealed great accomplishment with Gatorade. In spite of inside adjustment and careful wholesome treatment, a few patients can't be freed from parenteral nourishment. These patients for the most part are those with fewer than 60 cm of small bowel remaining, loss of the ileum and ileocecal valve and loss of the colon. The idea of pharmacologic gut pay incorporates measures went for additionally upgrading inside adjustment and expanding the odds that even patients with troublesome cases can be freed from parenteral nourishment [27]. This approach incorporates arrangement of development hormone 0.03-0.14 mg/kg/day subcutaneously for a month, parenteral (0.16 g/kg/day) or enteral (30 g/day) glutamine supplementation, and a high-starch slim down with 55-60% of calories originating from sugars versus 20-25% from fat and 20% from protein.

Somatropin is a recombinant human growth hormone that produces anabolic and anticatabolic effect on various cells (eg, myocytes, lymphocytes, hepatocytes, adipocytes, hematopoietic cells). It exerts activity on detailed cell receptors, comprising insulin like growth factor-1 (IGF-1). Actions on the gut can be direct or mediated via IGF-1. Somatropin is specified to treat short-bowel syndrome in conjunction with nutritional support. The adult dosage is 0.1 mg/kg/day SC for up to 4 weeks (not to exceed 8 mg/day**).** **مرجع**Teduglutide, an analogue of naturally happening glucagon like peptide-2 (GLP-2), was accepted by the FDA in December 2012 for adults with short-bowel syndrome who is reliant on parenteral support. It binds to the GLP-2R receptors located in intestinal subpopulations of enteroendocrine cells, enteric neurons of the submucosal , myenteric plexus and subepithelial myofibroblasts. Initiation of these receptors outcomes in local release of intestinal mediators that increase intestinal absorptive capacity, leading to increased fluid and nutrient absorption**(25)**. In two clinical trials and two addition studies of patients randomly allocated to obtain teduglutide or placebo, those treated with teduglutide achieved 46% and 63% clinical replies, compared to 6% and 30% of those treated with placebo [28]. A decrease in the volume of parenteral nutrition after 24 weeks of treatment was perceived. Outcomes presented a mean reduction in parenteral nutrition of 2.5 L/week and 4.4 L/week in teduglutide-treated patients, matched with 0.9 L/week and 2.3 L/week in placebo-treated patients. Detailed medication treatments in short-bowel syndrome are mostly aimed at decreasing gastric hypersecretion or decreasing diarrhea [29]. Gastric hypersecretion might be treated by proton pump inhibitors (PPIs) or histamine-2 (H2) blockers in the initial postoperative period. In many patients, gastric hypersecretion severe sufficient to cause clinical issues is self-limited. Diarrhea is a more vexing problem. When the patient is on nothing by mouth (NPO), codeine (60 mg IM q4hr) can be supportive. When enteral intake is continued, Imodium (4-5 mg q6hr) or Lomotil (2.5-5 mg q6hr) is useful. In refractory cases, tincture of opium (5-10 mL q4hr) could be tried**(24)**.

CONCLUSION

The treatment approaches of short bowel syndrome have expanded over the last 20 years.

New surgical procedures and innovative medical and nutritional inventions are used to develop survival and quality of life in patients with short bowel syndrome. Research of new fields may lead to a more successful and definite treatment of short bowel syndrome.

REFERENCES

1. **Efsen E and Jeppesen PB(2011):** Modern treatment of adult short bowel syndrome patients. Minerva Gastroenterol. Dietol. , 57(4):405-417.
2. **Weih S, Kessler M, Fonouni H, Golriz M, Hafezi M, Mehrabi A *et al.* (2011):**Current practice and future perspectives in the treatment of short bowel syndrome in children-a systematic review. Langenbecks Arch Surg., https://www.ncbi.nlm.nih.gov/pubmed/22105773
3. **Uchino M, Ikeuchi H, Bando T, Matsuoka H, Takahashi Y, Takesue Y *et al.* (2011):**Risk factors for short bowel syndrome in patients with Crohn's disease. Surg. Today, www.ncbi.nlm.nih.gov/pubmed?itool=pubmed_Abstract...retmode=ref
4. **Wilmore DW, Dudrick SJ, Daly JM *et al.*(1971):** The role of nutrition in the adaptation of the small intestine after massive resection. Surg. Gynecol. Obstet., 132(4):673-680.
5. **Wilmore DW and Dudrick SJ (1968):** Growth and development of an infant receiving all nutrients exclusively by vein. JAMA. , 203(10):860-864.
6. **Taha AM, Sharif K, Johnson T, Clarke S, Murphy MS and Gupte GL(2012):** Post script: long-term outcomes of isolated liver transplantation for short bowel syndrome and intestinal failure associated liver disease. J. Pediatr. Gastroenterol .Nutr., https://www.ncbi.nlm.nih.gov/pubmed/22167020
7. **Sellin JH (1998):** Intestinal electrolyte absorption and secretion. In:Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 6th ed. WB Saunders Co., Philadelphia, pp: 1451-1471.
8. **Clarke RM (1970):** Mucosal architecture and epithelial cell production rate in the small intestine of the albino rat. J. Anat., 107:519-529.
9. **Johansson C(1975):** Studies of gastrointestinal interactions. Characteristics of the absorption pattern of sugar, fat and protein from composite meals in man. A quantitative study. Scand. J. Gastroenterol.,10 (1):33-42.
10. **Phillips SF and Giller J (1973):** The contribution of the colon to electrolyte and water conservation in man. J. Lab. Clin. Med.,81(5):733-746.
11. **Pomare EW, Branch WJ and Cummings JH (1985):** Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J. Clin. Invest., 75(5):1448-1454.
12. **Wilmore DW, Byrne TA and Persinger RL (1997):** Short bowel syndrome: new therapeutic approaches. Curr. Probl. Surg.,34(5):389-444.
13. **Byrne TA, Persinger RL, Young LS *et al.* (1995):** A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann. Surg., 222(3):243-254.
14. **Vanderhoof JA and Langnas AN (1997):** Short-bowel syndrome in children and adults. Gastroenterology, 113(5):1767-1778.
15. **Puder M, Valim C, Meisel JA *et al.*(2009):** Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg., https://www.ncbi.nlm.nih.gov/pubmed/19661785
16. **Moreno JM, Planas M, Lecha M *et al.*(2005):** The year 2002 national register on home-based parenteral nutrition. Nutr. Hosp.,20(4):249-253.
17. **Thompson JS and Langnas AN (1999):** Surgical approaches to improving intestinal function in the short-bowel syndrome. Arch Surg.,134 (7):706-709.
18. **Panis Y, Messing B, Rivet P *et al.*(1997):** Segmental reversal of the small bowel as an alternative to intestinal transplantation in patients with short bowel syndrome. Ann. Surg.,225(4):401-407.
19. **Javid PJ, Kim HB, Duggan CP *et al.* (2005):** Serial transverse enteroplasty is associated with successful short-term outcomes in infants with short bowel syndrome. J. Pediatr. Surg.,40(6):1019-23.
20. **Oliveira C, de Silva N and Wales PW (2002):** Five-year outcomes after serial transverse enteroplasty in children with short bowel syndrome. J. Pediatr. Surg.,47(5):931-937.
21. **Abu-Elmagd K, Reyes J, Todo S *et al.*(1998):** Clinical intestinal transplantation: new perspectives and immunologic considerations. J. Am. Coll. Surg.,186(5):512-525.
22. **Vanderhoof JA and Langnas AN(1997):** Short-bowel syndrome in children and adults. Gastroenterology, 113(5):1767-1778.
23. **Abu-Elmagd K, Fung J, Bueno J *et al.*(2000):** Logistics and technique for procurement of intestinal, pancreatic, and hepatic grafts from the same donor. Ann. Surg., 232(5):680-687.
24. **Booth IW(1994):** Enteral nutrition as primary therapy in short bowel syndrome. Gut, 35(1):S69-72.
25. **Carbonnel F, Cosnes J, Chevret S *et al.*(1996):** The role of anatomic factors in nutritional autonomy after extensive small bowel resection. J. Parenter. Enteral .Nutr.,20(4):275-280.
26. **Nightingale JM, Lennard-Jones JE, Walker ER *et al.*(1990):** Jejunal efflux in short bowel syndrome. Lancet,336(8718):765-768.
27. **Wilmore DW, Lacey JM, Soultanakis RP *et al.* (1997):** Factors predicting a successful outcome after pharmacologic bowel compensation. Ann. Surg.,226(3):288-292.
28. **Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ *et al.*(2012):** Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology,143(6):1473-1481.
29. **Wallis K, Walters JR, Gabe S (2009):** Short bowel syndrome: the role of GLP-2 on improving outcome. Curr. Opin. Clin. Nutr. Metab. Care,12(5):526-532.